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Background: The aim of the present study was to compare the clinical efficacy of radical nephrectomy (RN) with
nephron-sparing surgery (NSS) in treating patients with localized renal cell carcinoma (RCC).
Methods: The literature search was performed in PubMed, MEDLINE Springer, Elsevier Science Direct, Cochrane
Library, and Google Scholar up to December 2012. The software Review Manager 5.1 and the STATA software
package v.11.0 were used for analyses. The odds ratios (ORs) and its 95% confidence interval (95% CI) were
calculated for comparison. Subgroup analyses were performed based on the tumor size of RCC.
Results: In total, 10 studies with 10,174 RCC patients (7,050 treated with RN and 3,124 treated with NSS) were
selected. The pooled estimate (OR = 1.58, 95% CI = 1.15–2.15, P = 0.004) showed a significantly lower rate of
cancer-specific deaths in the patients treated with NSS compared to RN. However, no statistically significant
differences were found in the rate of tumor recurrence (OR = 0.84, 95% CI = 0.67–1.06, P = 0.14) and complications
(OR = 0.91, 95% CI = 0.51–1.63, P = 0.74) between the patients treated with NSS and RN. In addition, all the subgroup
analyses presented consistent results with the overall analyses.
Conclusions: NSS had no significantly different from RN in tumor recurrence and complications for localized RCC.
However, the significantly lower rate of cancer-specific deaths supported the use of NSS not only for RCC with tumor
size >4.0 cm but also for tumor sizes ≤4.0 cm compared with RN.
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Renal cell carcinoma (RCC) is the third most common
malignancy of the genitourinary system characterized by
lack of early warning signs, protean clinical manifesta-
tions, and resistance to radiotherapy and chemotherapy
[1]. RCC patients account for approximately 3% of the
adults with malignancy and 90% to 95% of the patients
with neoplasms arising from the kidney [2]. In spite of
the rapid development of medical technology, RCC re-
mains a difficult malignancy to treat because of its ability
to spread asymptomatically and its inherent resistance to
conventional chemotherapy [3].* Correspondence: hannanahan@hotmail.com
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unless otherwise stated.Currently, the available treatments for RCC consist of
partial and radical nephrectomy (RN) [4]. Since the pub-
lication of Robson’s study in 1969 [5], RN has been
regarded as the gold standard to treat localized RCC [6].
However, nephron-sparing surgery (NSS) has been in-
creasingly advocated in recent years and has challenged
this concept [7]. The main advantage of NSS is that it
can preserve renal function after the removal of renal tu-
mors [8]. However, whether NSS is a better treatment than
RN for RCC still remains controversial. A recently pub-
lished article reported that NSS substantially reduced the
incidence of moderate renal dysfunction when compared
with RN [9]. Another study showed that NSS seemed to be
significantly less effective than RN in terms of overall sur-
vival in the intention-to-treat population [10].
Thus, in order to find the appropriate treatment for the
patients with localized RCC and provide much neededhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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analysis to compare the clinical efficacy of RN with NSS
in patients with localized RCC.
Methods
Search strategy
We searched several public databases including PubMed,
MEDLINE, Springer, Elsevier Science Direct, Cochrane
Library, and Google Scholar up to December 2012.
The key words “radical nephrectomy”, “nephron-sparing
surgery”, “partial nephrectomy”, “renal cell carcinoma”,
“renal tumor”, and “study” or “trial” were used to retrieve
the potentially relevant literature. Meanwhile, the refer-
ences of all relevant articles retrieved from above database
were searched for any additional studies.
Inclusion and exclusion criteria
The inclusion criteria were: i) the participants were patients
with localized RCC; ii) the investigations of the patients
were conducted during cardio pulmonary resuscitation
after cardiac arrest; iii) the studies were prospective, retro-
spective, or cross-sectional studies; iv) the patients were
divided into two treatment groups according to type of
surgery (RN and NSS groups); v) the clinical outcomes,
such as cancer-specific death, tumor recurrence, or com-
plications, were investigated. We excluded the studies by
the following criteria: i) only one treatment was investi-
gated in the studies; ii) the studies did not compare results
between RN and NSS; iii) the studies were non-original ar-
ticles such as conferences, reviews, or reports. In addition,
in cases of duplicate publication, only the study containing
the most complete data was included.
Data extraction and quality assessment
Two investigators independently extracted and assessed
the information with the standard protocol and contacted
the authors of included studies to obtain further informa-
tion. Discrepancies were resolved through discussion with
our research team or by contacting the original investiga-
tors. The data extracted from each study included general
information (first author’s name, year of publication, coun-
try), participant information (sample size, age and gender
of the patients in each group, tumor stage and size of pa-
tients), study design, and outcomes. When no appropriate
quality evaluation criteria were found, the study quality
was assessed by investigating the study methods, sample
size, and design.
Statistical analysis
The meta-analysis was performed by using the software
Review Manager 5.1 and the STATA software package
v.11.0. The odds ratios (ORs) and its 95% confidence
interval (95% CI) as summary statistics were calculated to
assess the treatment efficacy. The heterogeneity amongthe studies was evaluated by testing Cochran’s Q-statistic
[11] and I2 statistic [12] with P <0.10 or I2 > 50, respect-
ively. The pooled estimates of ORs were obtained by using
the DerSimonian and Laid method in the random effects
model [13]. The significance of the pooled ORs was deter-
mined by the Z-test (P <0.05).
In addition, it has been reported that different tumor
sizes in RCC are associated with the clinical outcomes of
treatment [14]. Therefore, subgroup analyses were per-
formed based on the tumor size of localized RCC. Mean-
while, in order to test the reliability of the results, the
sensitivity analysis was performed by sequential omission
of individual studies. The funnel plot and Egger’s test




A total of 908 potentially relevant articles were identified
by initial search. The selection process is shown in Figure 1.
Following removal of duplicated studies, 248 studies were
retained. Then by scanning the titles and abstracts, 172
obviously irrelevant articles were excluded. Finally, 10
studies met the inclusion criteria following exclusion of 30
studies that lacked the required data and 36 studies that
did not report the comparison between RN and NSS.
Characteristics of included studies
A total of 10 eligible studies [6,15-23] comprising 10,174
RCC patients (7,050 patients treated by RN and 3,124
patients treated by NSS) were included in the meta-
analysis. The characteristics of these studies are shown
in Table 1. The included studies were published from
2000 to 2012. The follow-up duration of these studies
ranged from 10 to 208 months. The tumor stage and
size varied between the studies.
The results of statistical analysis
Cancer-specific death was assessed in five of the included
studies [6,16,19,20,23]. The test of heterogeneity indicated
that there was no significant heterogeneity (I2 = 30.0%,
P = 0.22) among these studies. The overall pooled es-
timate (OR = 1.58, 95% CI =1.15–2.14, P = 0.0004) showed
that there was a lower cancer-specific death rate in the
NSS group compared with the RN group (Figure 2A).
A total of five included studies reported the tumor re-
currence of the patients [15,16,18-20]. No significant het-
erogeneity (I2 = 0.0%, P = 0.43) was identified. The overall
pooled estimate (OR = 0.84, 95% CI = 0.67–1.06, P = 0.14)
demonstrated that no significant difference existed be-
tween the two groups (Figure 2B).
Six studies [15,17-19,21,22] assessed the patient compli-
cations. The test of heterogeneity indicated a significant
heterogeneity (I2 = 71.0%, P <0.01) among these studies.
Figure 1 Flow diagram of screening studies.
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0.51–1.63, P =0.74) did not show a significant differ-
ence in postoperative complication rate between RN
and NSS group (Figure 2C).
Subgroup analyses
The results of the subgroup analyses by tumor size are
shown in Table 2. For all the subgroup analyses, the results
of each indicator were consistent with the overall analysis
(tumor size ≤4.0 cm: cancer-specific death, OR =1.69, 95%
CI = 1.22–2.35, P =0.002; tumor recurrence, OR = 0.83,
95% CI = 0.66–1.05, P =0.13; complications, OR = 1.10,










Lau et al. [15] 2000 T1 3.3a*, 3.7b* 120
Shinohara et al. [19] 2000 T1, T2, T3 <4.0 12 to 131
Poulakis et al. [17] 2003 NP 6.9a*, 3.9b* 14 to 27
Patard et al. [16] 2004 T1 4.0# 10 to 208
Becker et al. [6] 2006 T1, T2, T3 3.7* 66*
Mitchell et al. [18] 2006 T1, T2, T3 5.2* 44#
Van Poppel et al. [21] 2007 T0,T1,T2,T3 <4.0 60
Antonelli et al. [20] 2012 T1,T3 >4.0 25 to 85
Huang et al. [23] 2009 NP <4.0 48#
Gratzke et al. [22] 2009 T1, T2, T3 NA 11 to 71
SD, Standard deviation; RN, Radical nephrectomy; NSS, Nephron-sparing surgery; *,specific death, OR =1.36, 95% CI =1.01–1.85, P = 0.04;
tumor recurrence, OR = 0.87, 95% CI = 0.36–2.11, P = 0.76;
complications, OR = 0.71, 95% CI = 0.44–1.13, P = 0.15) in-
dicated consistent results with the overall analysis. However,
inconsistent results are shown in the heterogeneity test. The
heterogeneity among studies was significant in the overall
analysis of complications. However, no significant hetero-
geneity among the studies was found in the analysis of
tumor size >4.0 cm for complications (I2 = 0.0%, P =0.88).
Sensitivity analysis and publication bias
No inconsistent results were observed in the sensitivity










164 NA NA 164 NA NA
51 59 37 (73) 15 61 13 (87)
199 65.2 ± 11.0 121 (61) 158 62.6 ± 9.9 110 (70)
1075 60.0 ± 12.4 692 (64) 379 59.7 ± 12.3 253 (67)
369 60.2 225 (61) 241 59.4 150 (62)
66 66.9 44 (67) 33 68.9 26 (79)
273 NA 178 (65) 268 NA 178 (66)
2345 62.5 1505 (64) 1,266 60.1 881 (70)
2435 NA 1362 (56) 556 NA 351 (63)
73 NA 46 (63) 44 60.7 ± 12.4 29 (66)
Mean; #, Median; a, RN group; b, NSS group; NA, Not clear.
Figure 2 Forest plots of cancer-specific death (A), tumor recurrence (B), and complications (C).
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proved. No evidence of publication bias was shown by the
funnel plot (Figure 3) and Egger’s test (P >0.1, Table 2).
Discussion
RCC is the most common cancer of the kidney. Currently,
there is controversy regarding the clinical efficacy of NSS
and RN in treating RCC. Thus, we performed this meta-
analysis to compare the clinical efficacy of NSS and RN.
The results showed that NSS had a significantly lower
cancer-specific death rate compared with RN for RCC pa-
tients although there was no significant difference in the
rate of tumor recurrence and complications between the
patients treated by NSS or RN.Our results confirm that NSS treatment has a signifi-
cantly lower cancer-specific death rate compared to RN
for patients with localized RCC. Based on its characteris-
tics, NSS can protect from renal function loss associated
with the removal of the full renal unit, as is performed
in RN [24]. Further, Bouliere et al. reported that NSS is
superior to RN in preserving renal function outcome
even when expanding NSS indications beyond the trad-
itional 4 cm cut-off [25]. Thus, the survival of patients
treated with NSS may be increased due to less kidney
damage compared to RN. This may be the cause for the
lower cancer-specific death rate of patients treated with
NSS compared to that of RN. Thus, NSS should be sup-
ported for the treatment of RCC. Robert et al. [26]
Table 2 Statistical analysis results
Subgroup
of tumor size
Sample size No. of studies Meta-analysis Test of heterogeneity Egger’s test
Case Control OR (95% CI) P value P value I2 (%) P value
Cancer-specific death
Overall 6,275 2,457 5 [6,16,19,20,23] 1.58 (1.15 to 2.15) 0.004 0.22 30.0 0.27
≤4.0 cm 3,930 1,191 4 [6,16,19,23] 1.86 (1.11 to 3.13) 0.002 0.17 41 –
>4.0 cm 2,345 1,266 1 [20] 1.36 (1.01 to 1.85) 0.04 – – –
Tumor recurrence
Overall 3,701 1,857 5 [15,16,18-20] 0.84 (0.67 to 1.06) 0.14 0.43 0.0 0.58
≤4.0 cm 1,290 558 3 [15,16,19] 0.67 (0.27 to 1.64) 0.38 0.16 45 –
>4.0 cm 2,411 1,299 2 [18,20] 0.87 (0.36 to 2.11) 0.76 0.68 0 –
Complications
Overall 826 682 6 [15,17-19,21,22] 0.91 (0.51 to 1.63) 0.74 <0.01 71.0 0.76
≤4.0 cm 488 477 3 [15,19,21] 1.10 (0.31 to 3.92) 0.88 0.0004 87 –
>4.0 cm 265 191 2 [17,18] 0.71 (0.44 to 1.13) 0.15 0.88 0 –
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lent direct hospital costs and length of stay when com-
pared with patients undergoing radical nephrectomy
for small solitary RCCs. Another article reported that
nephron-sparing surgery was the standard of care for
small RCC [27]. Thus, the comparison of efficacy be-
tween NSS and RN with regards to other indicators
still requires further evaluation.
In addition, the subgroup analysis showed the consistent
results with the overall analysis, suggesting that tumor size
did not influence the results of this study. NSS can be ap-
plied not only for RCC with tumor sizes >4.0 cm but also
for tumors ≤4.0 cm compared with RN. However, the het-
erogeneity test indicated that no significant heterogeneity
among the studies was found in the analysis of tumor
size >4.0 cm for complications, while significant het-
erogeneity was found in the analysis of tumor size ≤4.0 cm
and in the overall analysis. Therefore, tumor size is one of
the sources of heterogeneity. Nevertheless, further studiesFigure 3 Funnel plot of complications.are needed to explore other sources of heterogeneity.
Moreover, clinical efficacy of NSS has been proven to be
highly associated with different tumor stages or grades of
RCC. Fergany et al. [28] reported that cancer-specific
death was significantly affected by tumor stage in patients
treated with NSS. In this meta-analysis, the tumor stage
was different in each study and therefore no appropriate
grouping could be used for subgroup analysis. Hence, fur-
ther studies should focus on the influence of different
tumor stages on the clinical efficacy of NSS vs. RN.
Finally, some limitations of this study should be men-
tioned. First, only published studies were included in this
meta-analysis; thus, the grey literature may be omitted.
Second, significant heterogeneity among the included
studies was found in the indicators of complication. The
sources of heterogeneity need be explored in further
studies. Third, only three indicators were used to assess
the clinical efficacy of RN and NSS, other indicators
should be considered in further studies. In addition, the
included studies were not randomized controlled trials
or case-control studies, and therefore the quality evalu-
ation criteria of the studies were not determined. Thus,
more studies need to be performed to verify the results
of this meta-analysis.
Conclusions
In conclusion, we compared the clinical efficacy of RN
in treating localized RCC with NSS in this meta-analysis.
The results showed that NSS treatment had a better
clinical efficacy than RN for patients with localized RCC.
However, more studies must be performed to verify the
results of this meta-analysis.
Abbreviations
95% CI: Confidence interval; NSS: Nephron-sparing surgery; ORs: Odds ratios;
RCC: Renal cell carcinoma; RN: Radical nephrectomy.
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